EP0457875A1 - Anticorps a10 chimerique souris-humain avec specificite envers un antigene de cellule tumorale humaine - Google Patents

Anticorps a10 chimerique souris-humain avec specificite envers un antigene de cellule tumorale humaine

Info

Publication number
EP0457875A1
EP0457875A1 EP91900650A EP91900650A EP0457875A1 EP 0457875 A1 EP0457875 A1 EP 0457875A1 EP 91900650 A EP91900650 A EP 91900650A EP 91900650 A EP91900650 A EP 91900650A EP 0457875 A1 EP0457875 A1 EP 0457875A1
Authority
EP
European Patent Office
Prior art keywords
antibody
alo
fragment
chain
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91900650A
Other languages
German (de)
English (en)
Other versions
EP0457875A4 (en
Inventor
Marc D. Better
Arnold H. Horwitz
Shau-Ping Lei
Randy R. Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Xoma Corp
Original Assignee
Green Cross Corp Japan
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Xoma Corp filed Critical Green Cross Corp Japan
Publication of EP0457875A1 publication Critical patent/EP0457875A1/fr
Publication of EP0457875A4 publication Critical patent/EP0457875A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved

Definitions

  • This invention relates to antibodies, and their derivatives, with specificity for a human tumor antigen, to nucleotide and protein sequences coding therefor, and to methods of obtaining and manipulat ⁇ ing such sequences.
  • mAb Monoclonal antibody
  • mAb Monoclonal antibody
  • mouse mAbs Although they display extraordinarily specificity and can influence the progression of human disease, mouse mAbs, by their very nature, have limitations in their applicability to human medicine. Most obviously, since they are derived from mouse cells, they are recognized as foreign proteins when introduced into humans and elicit immune responses. Similarly, since they are distinguished from human proteins, they are cleared rapidly from circulation.
  • Chimeric antibody technology such as that used for the anti ⁇ bodies described in this invention, bridges both the hybridoma and genetic engineering technologies to provide reagents, as well as products derived therefrom, for the treatment and diagnosis of human cancer.
  • the invention provides an engineered chimeric antibody of desired variable (V) region specificity and constant (C) region properties, produced after gene cloning and expression of immunoglobulin light (L) and heavy (H) chains.
  • V variable
  • C constant
  • the chimeric antibody and its derivatives which are specific for human tumor antigens may have applicability in the diagnosis and treatment of human cancer.
  • the cloned immunoglobulin gene products and their derivatives can be produced in mammalian or microbial cells.
  • the invention provides cDNA sequences coding for immunoglobulin heavy and light chains comprising a human C region and a non-human V region.
  • the invention provides sequences as above, present in recombinant DNA molecules in vehicles such as plasmid vectors, capable of expres ⁇ sion in desired prokaryotic or eukaryotic hosts.
  • the invention provides hosts capable of producing the chimeric antibodies and methods of using these hosts.
  • the invention also provides individual chimeric immunoglobulin chains, as well as complete assembled molecules having human C regions and mouse V regions with specificity for human tumor cell antigens, wherein both V regions have the same binding specificity.
  • immunoglobulin chains and/or molecules provided by the invention are:
  • An antibody with monovalent specificity for a human tumor cell antigen i.e., a complete, functional immunoglobulin molecule comprising:
  • Antibody fragments such as Fab, Fab', and F(ab')2- Genetic sequences, especially cDNA sequences, coding for the aforementioned combinations of chimeric chains are also provided herein.
  • the invention also provides for a genetic sequence, especially a cDNA sequence, coding for the V region of desired specificity of an antibody H and/or L chain, linked to a sequence coding for a polypep- tide different from an immunoglobulin chain (e.g., an enzyme).
  • a genetic sequence especially a cDNA sequence, coding for the V region of desired specificity of an antibody H and/or L chain, linked to a sequence coding for a polypep- tide different from an immunoglobulin chain (e.g., an enzyme).
  • FIGURE 1 Nucleotide sequence of the coding strand for the AlO H chain mouse V region. Shown is the nucleotide sequence from the end of the oligo-dC tail to the JH2-C
  • FIGURE 2 Nucleotide sequence of the coding strand for the AlO mouse kappa V region (V ⁇ ). Shown is the nucleotide sequence from the end of the oligo-dC tail to the J ⁇ -C ⁇ junction. Also shown is the amino acid sequence deduced from the nucleotide sequence. Shown in bold are the oligonucleotides used for site directed mutagenesis and the sites at which restriction site modifications were made.
  • FIGURE 3 Construction scheme for the chimeric mouse-human AlO heavy chain mammalian expression plasmid, pING2254.
  • the V region of the cDNA clone p ⁇ A10-16 was engineered to be compatible with the eukaryotic expression plasmid pING2227.
  • Plasmid pING2227 contains the following gene regulatory elements useful for expression in mammalian cells: 1) the IgG H chain enhancer element, 2) an Abelson LTR promoter, 3) the SV40 16S splice site, and 4) the IgG H chain polyadenylation signal sequence. It also contains the entire human IgGl C region from pGMH-6 (Liu, A. Y. et al,, Proc. Natl .
  • FIGURE 4 Construction scheme for the chimeric mouse-human AlO light chain mammalian expression plasmid pING2252.
  • the V region from the cDNA clone pKA10-16 was engineered to be compatible with the eukaryotic expression plasmid pING1712.
  • Plasmid pING1712 contains the following gene regulatory elements useful for expression in mammalian cells: 1) the IgH enhancer element, 2) the Abelson LTR promoter, 3) the SV40 16S splice site, and 4) a human K polyadenylation signal sequence. It also contains the entire human C ⁇ region (Liu, A.Y., et al. supra) and the GPJ gene which allows for ycophenolic acid resistance in transfected cells.
  • FIGURE 5 Construction scheme for the bacterial chimeric AlO Fab expression plasmid pING3204.
  • Plasmid pING3204 contains the following elements useful for expression in E. coli: 1) the araC gene, 2) the inducible araB promoter, 3) the dicistronic Fd and K AlO genes fused to the pelB leader sequence, 4) the trpA transcription termination sequence, and 5) the tetR gene, useful for selection in E. coli.
  • FIGURE 6 Yeast expression plasmids for Fab expression. Shown are the yeast expression plasmids containing the AlO chimeric L chain gene fused to the yeast PGK promoter, invertase signal sequence and PGK polyadenylation signal, a; the similar yeast plasmid contains the Fd gene, b; the yeast expression plasmid containing the L chain promoter/leader fusion with PGK transcription termination signal, c; similar yeast plasmid containing the Fd gene, d; and the final 2 gene yeast expression plasmid pING3203, e.
  • the invention provides an antibody that can be used for the treatment and diagnosis of human carcinoma, either alone or in combination with other reagents.
  • the antigen is that bound by the mAb called AlO.
  • the method of production combines five elements:
  • mRNA messenger RNA
  • J region One common feature of all immunoglobulin L and H chain genes and the encoded messenger RNAs is the so-called J region.
  • have different sequences, but a high degree of sequence homology exists (greater than 80%) among each group, especially near the C region. This homology is exploited in this invention wherein consensus sequences of J
  • C region cDNA module vectors prepared from human cells and modified by site-directed mutagenesis to place a restriction site at the analogous position in the human sequence were used. For example, one can clone the complete human *c chain C region (C ⁇ ) and the complete human gammal C region (C ⁇ l).
  • An alternative method utilizing genomic C region clones as the source for C region module vectors would not allow these genes to be expressed in hosts such as bacteria where enzymes needed to remove intervening sequences are absent.
  • V region segments are excised and ligated to CL or C ⁇ module vectors.
  • human ga mal region can be modified by introducing a termination codon thereby generating a gene sequence which encodes the H chain portion of an Fab molecule.
  • the coding sequences with linked V and C regions are then transferred into appropriate expression vehicles for expression in appropriate hosts, prokaryotic or eukaryotic.
  • Two coding DNA sequences are said to be "operably linked” if the linkage results in a continuously translatable sequence without alteration or interruption of the triplet reading frame.
  • a DNA coding sequence is operably linked to a gene expression element if the linkage results in the proper function of that gene expression element to result in expression of the coding sequence.
  • Expression vehicles include plasmids or other vectors. Preferred among these are vehicles carrying a functionally complete human C ⁇ or CL chain sequence having appropriate restriction sites engineered so that any V ⁇ or V chain sequence with appropriate cohesive ends can be easily inserted. Human C or CL chain sequence-containing vehicles are thus an important embodiment of the invention. These vehicles can be used as intermediates for the expression of any desired complete H or L chain in any appropriate host.
  • yeast provides substantial advantages for the production of immunoglobulin L and H chains. Yeasts carry out post-translational peptide modifications including glycosylation. A number of recombinant DNA strategies now exist which utilize strong promoter sequences and high copy number plasmids which can be used for production of the desired proteins in yeast. Yeast recognizes leader sequences of cloned mammalian gene products and secretes peptides bearing leader sequences (i.e. prepeptides) (Hitzman, et al . , 11th International Conference on Yeast, Genetics and Molecular Biology, adjoin, France, September 13-17, 1982).
  • Yeast gene expression systems can be routinely evaluated for the levels of production, secretion and the stability of chimeric H and L chain proteins and assembled chimeric antibodies. Any of a series of yeast gene expression systems incorporating promoter and termination elements from the actively expressed genes coding for glycolytic enzymes produced in large quantities when yeasts are grown in media rich in glucose can be utilized. Known glycolytic genes can also provide very efficient transcription control signals. For example, the promoter and terminator signals of the iso-1-cytochrome C (CYC-1) gene can be utilized. A number of approaches may be taken for evaluating optimal expression plasmids for the expression of cloned immunoglobulin cDNAs in yeast.
  • CYC-1-cytochrome C CYC-1-cytochrome C
  • Bacterial strains may also be utilized as transformation hosts for the production of antibody molecules or antibody fragments described by this invention.
  • E. coli strains such as E. coli W3110 (ATCC 27325) and other enterobacteria such as Salmonella typhimurium or Serratia marcescens, and various Pseudomonas species may be used.
  • Plasmid vectors containing replicon and control sequences which are derived from species compatible with a host cell are used in connection with these bacterial hosts.
  • the vector carries a replica ⁇ tion site, as well as specific genes which are capable of providing phenotypic selection in transformed cells.
  • a number of approaches may be taken for evaluating the expression plasmids for the production of chimeric antibodies or antibody chains encoded by the cloned immuno ⁇ globulin cDNAs in bacteria.
  • Mammalian cells are grown in vitro or in vivo.
  • Mammalian cells provide post-translational modifications to immunoglobulin protein molecules including leader peptide removal, folding and assembly of H and L chains, glycosylation of the antibody molecules, and secretion of functional antibody protein.
  • Mammalian cells which may be useful as hosts for the production of antibody proteins include cells of lymphoid origin, such as the hybridoma Sp2/0-Agl4 (ATCC CRL 1581) or the myeloma P3X63Ag8 (ATCC TIB 9), and its derivatives. Others include cells of fibroblast origin, such as Vero (ATCC CRL 81) or CHO- Kl (ATCC CRL 61).
  • H and L chain genes are available for the expression of cloned H chain and L chain genes in mammalian cells. Different approaches can be followed to obtain complete H2L2 antibodies. It is possible to co-express H and L chains in the same cells to achieve intracellular association and linkage of H and L chains into complete tetrameric H L2 antibodies. The co-expression can occur by using either the same or different plasmids in the same host. Genes for both H and L chains can be placed into the same plasmid, which is then transfected into cells, thereby selecting directly for cells that express both chains.
  • cells may be transfected first with a plasmid encoding one chain, for example the L chain, followed by transfection of the resulting cell line with a H chain plasmid containing a second selectable marker.
  • Cell lines producing H2L2 molecules via either route could be transfected with plasmids encoding additional copies of H, L, or H plus L chains in conjunction with additional selectable markers to generate cell lines with enhanced properties, such as higher production of assembled (H L2) antibody molecules or enhanced stability of the transfected cell lines.
  • the invention provides "chimeric" immunoglobulin chains, either H or L, with specificity toward human tumor cells.
  • a chimeric chain contains a C region substantially similar to that present in a natural human immunoglobulin, and a V region having the desired anti-tumor specificity of the invention.
  • the invention also provides immunoglobulin molecules having H and L chains associated so that the overall molecule exhibits the desired binding and recognition properties.
  • immunoglobulin molecules having H and L chains associated so that the overall molecule exhibits the desired binding and recognition properties.
  • Various types of immunoglobulin molecules are provided: monovalent, divalent, or molecules with the invention's V binding domains attached to moieties carrying desired functions.
  • Various types of immunoglobulin molecules are provided: mono ⁇ valent, divalent, or molecules with the invention's V region binding domains attached to moieties carrying desired functions.
  • This invention also provides for "fragments" of chimeric immunoglobulin molecules, which include Fab, F(ab'), and F(ab')2 molecules.
  • the invention also provides for "derivatives" of the chimeric immunoglob- ulins, which term includes those proteins encoded by truncated or modifed genes to yield molecular species functionally resembling the immunoglobulin fragments.
  • the modifications include, but are not limited to, addition of genetic sequences coding for cytotoxic proteins such as plant and bacterial toxins and tumor necrosis factor (TNF).
  • TNF tumor necrosis factor
  • Antibodies, fragments or derivatives having chimeric H chains and L chains of the same or different V region binding specificity can be prepared by appropriate association of the individual polypeptide chains, as taught, for example by Sears, D.W. et al . (Proc. Natl . Acad. Sci. USA 72:353-357 (1975)). With this approach, hosts expressing chimeric H chains (or their derivatives) are separately cultured from hosts expressing chimeric L chains (or their deriva ⁇ tives), and the immunoglobulin chains are separately recovered and then associated. Alternatively, the hosts can be co-cultured and the chains allowed to associate spontaneously in the culture medium, followed by recovery of the assembled immunoglobulin, fragment or derivative.
  • the antibodies of this invention can be adapted for therapeutic efficacy by virtue of their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) against tumor cells.
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • an endogenous source or an exogenous source of effector cells (for ADCC) or complement components (for CDC) can be utilized.
  • the chimeric antibodies of this invention, their fragments, and derivatives can be used therapeutically as immunoconjugates (see for review: Dillman, R.O., Ann. Int. Med. 111:592-603 (1989)). They can be coupled to cytotoxic proteins, including, but not limited to Ricin- A, Pseudomonas toxin, Diptheria toxin, and TNF.
  • Toxins conjugated to antibodies or other ligands are known in the art (see, for example, Olsnes, S. et al.. Immunol . Today I0_:291-295 (1989)). Plant and bacterial toxins typically kill cells by disrupting the protein synthetic machinery.
  • the chimeric antibodies of this invention can be conjugated to additional types of therapeutic moieties including, but not limited to, radionuclides and cytotoxic agents, to treat cancer patients.
  • therapeutic moieties including, but not limited to, radionuclides and cytotoxic agents, to treat cancer patients.
  • radionuclides which can be coupled to antibodies and delivered in vivo to sites of antigen include 212 Bi, 131 I, 185 Re, and 90 Y, which list is not intended to be exhaustive.
  • the radionuclides exert their cytotoxic effect by locally irradiating the cells, leading to various intracellular lesions, as is known in the art of radiotherapy.
  • Cytotoxic drugs which can be conjugated to antibodies and subsequently used for in vivo therapy include, but are not limited to, daunorubicin, doxorubicin, ethotrexate, and Mitomycin C. Cytotoxic drugs interfere with critical cellular processes including DNA, RNA, and protein synthesis. For a fuller exposition of these classes of drugs which are known in the art, and their mechanisms of action, see Goodman, A.G., et al.. Goodman and Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS. 7th Ed., Macmillan Publishing Co., 1985).
  • Treatment of an individual with a tumor bearing the antigen recognized by the antibodies, fragments or derivatives of this invention comprises parenterally ad ininstering a single or multiple doses of the antibody, fragment or derivative.
  • the effective dose is a function of the individual chimeric antibody, the presence and nature of a conjugated therapeutic agent (see above), the patient and his clinical status, and can vary from about 10 ng/kg body weight to about 100 mg/kg body weight.
  • the route of administration may include intratumoral , intravenous, subcutaneous, intramuscular, intrapul- monary, intraperitoneal, intranasal, intrathecal, transdermal or other known routes.
  • chimeric antibodies, fragments or derivatives of this invention may be advantageously utilized in combination with other chimeric antibodies, or with lymphokines or hemopoietic growth factors, etc., which serve to increase the number or activity of effector cells which interact with the antibodies.
  • the antibodies of the invention having a complete or partial human C region can be introduced in vivo, especially in humans, with reduced negative immune reactions such as serum sickness or anaphylac- tic shock, as compared to whole mouse antibodies.
  • the antibodies can also be utilized in im unodiagnostic assays in detectably labelled form (e.g., enzymes, l ⁇ I, l ⁇ C, fluorescent labels, etc.), or in immobilized form (on polymeric tubes, beads, etc.).
  • detectably labelled form e.g., enzymes, l ⁇ I, l ⁇ C, fluorescent labels, etc.
  • immobilized form on polymeric tubes, beads, etc.
  • Such labelled or immobilized antibodies, fragments or derivatives may be provided in kits.
  • the antibodies, fragments and derivatives may also be utilized in labelled form for in vivo imaging, wherein the label can be a radioactive emitter, a nuclear magnetic resonance contrasting agent (such as a heavy metal nucleus), or an X-ray contrasting agent (such as a heavy metal).
  • the labels can also be used for in vitro localization of the recognized tumor cell antigen by appropriate labelling.
  • Mixed antibody-enzyme molecules can be used for immuno ⁇ diagnosis using assay methods such as ELISA.
  • the chimeric antibodies of this invention can be used for any and all uses in which the urine AlO mAb can be used, with the obvious advantage that the chimeric molecules are more compatible with the human body.
  • CEA carcinoembryonic antigen
  • the immune spleen cells and the mouse myeloma, P3U1 (Curr. Top. Microbiol. Immunol.. 81 . :1, 1979), were mixed in the ratio of about 2:1 (2.2 X 10 7 : 1.6 X 10 7 ) and a fusion reaction was carried out for 2 min. using 45% polyethylene glycol (average molecular weight: 4000) by a partial modification of the method of Kohler et al . (Immunological Methods. Academic Press, New York, p. 391, 1979). The treated cells were centrifuged, and the supernatant was discarded. The cells were then incubated for five minutes in HAT medium (see below) and inoculated into 96-well flat bottom microplates (0.1 ml per well) and cultured in 7.5% CO .
  • Dulbecco's modified Eagle medium (DMEM) was obtained from Nissui Seiyaku Co.
  • HAT medium was prepared by supplementing D-MEM with the following additives: 10% Horse serum (Flow Labora ⁇ tories); 300 mg/1 L-glutamine; 110 mg/1 Sodium pyruvate; 100 IU/ml Penicillin; 100 /.g/ml Streptomycin; 3.5 g/1 Glucose; 3.7 g/1 NaHC0 3 ; 1 x 10" 4 M Hypoxan- thine; 4 x 10 ⁇ 7 M Aminopterin; 1.6 x 10 " 5 M Thymidine 3.
  • the anti-CEA activity of each hybrido a culture supernatant was screened by the PHA method using sheep red blood cells coupled with CEA. Any wells producing anti-CEA antibodies were further screened by the PHA method using sheep red blood cells coupled with CEA through the anti-MKN-45 mAb, BD6. Selected hybridomas were cloned two or three times and their culture supernatants were checked for reactivity to cancer cell lines.
  • the hybridoma producing mAb AlO was deposited at the Fermentation Institute of Osaka (IFO) in Osaka, Japan on April 28, 1989 under accession number IFO 50188. 4. Characterization of AlO
  • AlO is an IgGl that binds to an antigen which is expressed on the surface of cells from many human carcinomas, including colon car ⁇ cinoma, and is only present at trace levels in normal adult cells.
  • Oligo-dG tailed pBR322, pUC18, pUC19, M13mpl8, and M13mpl9 were purchased from BRL (Gaithersburg, MD).
  • DNA manipulations involving purification of plasmid DNA by buoyant density centrifugation, restriction endonuclease digestion, purification of DNA fragments by agarose gel electrophoresis, ligation and transformation of E. coli were as described by Maniatis, T. et al ., Molecular Cloning: A Laboratory Manual . (1982) or other standard procedures. Restriction endonucleases and other DNA/RNA modifying enzymes were purchased from Boehringer-Mannheim (Indianapolis, IN), BRL, and New England Biolabs (Beverly, MA).
  • Oligo-dT primed cDNA libraries were prepared from poly(A)+ RNA by the methods of Gubler, V. et al . (Gene 25:263 (1983)). The cDNA was dC-tailed with terminal deoxynucleotide transferase and annealed to dG-tailed pBR322. cDNA libraries were screened by hybridization (Maniatis, T., supra) with 32 P-labelled, nick-translated DNA frag ⁇ ments, ie., for K clones with a mouse C ⁇ region probe and for H chain clones with a mouse IgGl C region probe .
  • the nucleotide sequences of the cDNA clones show that they are immunoglobulin V region clones as they contain amino acid residues diagnostic of V domains (Kabat et al . , Sequences of Proteins of Immunoloqjcal Interest. U.S. Dept. of HHS, 1983).
  • the AlO V ⁇ has the J
  • the L chain vector pING1712 was made by first making a plasmid DNA containing a test chimeric L chain gene (pING2122) and adding a mouse Abelson LTR promoter, a splice region, and a mouse genomic K region 3' to the polyadenylation signal.
  • the H chain mouse enhancer 0.7kb Xbal to EcoRI fragment from M13 M8alphaRX12 Robotson, R.R. " et al . PCT US86/02269 was inserted into Xbal plus EcoRI cut M13mpl9.
  • the enhancer-containing Hindlll to Bglll fragment was inserted into the Bglll to Hindi11 region of pSH6, an E. coli recombinant plasmid DNA that contains unique Xhol, Bglll, and Hindlll sites, in that order.
  • the enhancer-containing Xbal to Xhol fragment was then inserted into the enhancer Xbal to Xhol region of pING2121b, an expression plasmid identical to pING2108b (Liu, A.Y. et al ., J. immunology 139:3521 (1987)) except that the L6 V L region (Liu, A.Y. et al.. Proc. Nat! . Acad. Sci. USA 84:3439 (1987)) was used in its construction instead of the 2H7 V region.
  • the resulting plasmid was pING2122.
  • the mouse Abelson virus LTR was obtained from pelin2 (provided by Dr. Owen Witte, UCLA).
  • pel n2 contains the pl20 viral 3' LTR (Reddy, E.P. et al.. Proc. Nat! . Acad. Sci. USA 80:3623 (1983)) except that the Bglll site at viral position 4623 has been modified by insertion of the EcoRI oligonucleotide linker GGAATTCC.
  • the 0.8kb EcoRI to Kpnl fragment of pelin2 containing the pl20 3' LTR promoter was inserted into Kpnl plus EcoRI cut pUC18.
  • the LTR was excised as an EcoRI to Sail fragment and ligated to EcoRI plus Sail cut pING2122, resulting in a plasmid where the LTR promoter is adjacent to the L6 L chain gene (pING2126).
  • An Xhol to Sail fragment containing SV40 16S splice donor and acceptor sites was excised from pUC12/pLl (Robinson, et al ., supra) and inserted into the Sail site of pING2126, screening for the orientation where the splice donor was between the LTR and the L chain gene (pING2133).
  • the polyadenylation/transcription termination region of the K expression vector was also modified.
  • the first step was the Hindlll digestion and religation of plasmid pING2121a, which is identical to pING2108a (Liu, A.Y. et al.. supra) except that the L6 VL was used in its construction instead of the 2H7 VL, to form pING2121a-deltaH.
  • the l.lkb Bglll to BamHI fragment of mouse genomic DNA distal to the polyadenylation site (Xu, M. et al.. J. Biol. Chem. 261: 3838 (1986) was isolated from pS107A (provided by Dr.
  • the Abelson LTR promoter was also used in the chimeric H chain expression vector pING1714.
  • pING2111 Robot, R.R. et al .. supra
  • the Aatll to Sail fragment containing the Abelson LTR promoter was excised from pING2133 and ligated to the large Aatll to Sail fragment of pING1707 to form pING1711.
  • the H chain enhancer was deleted from pING1711 by EcoRI digestion, T4 polymerase treatment, ligation to Aatll oligonucleotide linker, and cleavage and religation with Aatll to form the 7.7kb expression vector pING1714.
  • a similar plasmid, pING2227 contains two additional regulatory elements, the IgH enhancer and the human genomic IgG polyadenylation sequence.
  • pING2227 is identical to pING1712 in the region from Bglll to Sail containing the IgH enhancer the Abelson LTR promoter, and the 16S splice donor and acceptor sites.
  • the human genomic IgG 3' end sequence was ligated as an 1185 bp Xmalll DNA fragment into an Xmalll site located 6 bp past the termination codon for the H chain gene in pING1714.
  • the 1300 bp Xmalll fragment containing the genomic gamma 3' end was isolated from a derivative of pHG3A (Ellison et al . 1982. Nuc. Acids Res. 10: 4071).
  • the J-region mutagenesis primer 5'-CTGAGGAGACGGTGACCGTGGTGCCTT-3' was used to insert a BstEII site into the M13 subclone pTKl generating pTK3, and the oligonucleotide 5'-ATGTCTGTGTCGACCACTGAAGA-3' was used to insert a Sail restriction site into ⁇ TK3 upstream of the initiation codon ATG, generating pTK7.
  • the J-region mutagenesis primer 5'-GTTTTATTTCAAGCTTGGTCC-3' was used to insert a Hindlll site into the M13 subclone pTK2 to generate pTK4, and the oligonucleotide 5'-GAACTTTGGTCGACAGCAACGGG-3' was used to insert a Sail restriction site into pTK4 upstream of the initiation codon ATG to generate pTK5.
  • the restriction fragment containing the AlO VL region bounded by Sail and Hindlll was then cloned into the expression vector pING1712 to generate the final chimeric AlO L chain expression vector, pING2252.
  • the cell line Sp2/0 (American Type Culture Collection # CRL1581) was grown in DMEM plus 4.5g/l glucose (GIBCO) plus 10% fetal bovine serum. Media were Supplemented with glutamine, penicillin, and streptomycin (GPS) (Irvine Scientific, Irvine, CA) .
  • the chimeric AlO L chain expression plasmid, pING2252 was linearized by digestion with Pvul restriction endonuclease and transfected into Sp2/0 cells, giving mycophenolic acid resistant clones which were screened for L chain synthesis. The best producer after outgrowth and subsequent subcloning, was transfected with Pvul-linearized pING2254, the expression plasmid containing the chimeric AlO H chain gene. After selection with G418, the clone producing the most L plus H chain, Sp2/0-2252 3C3.4D2-2254 6C4, secreted antibody at approximately 6 to 7 /_g//_l .
  • (a) Inhibition of Binding The mouse AlO mAb and chimeric AlO antibody were compared in a binding inhibition assay. Such inhibition assays are used to establish antigen recognition.
  • Mouse AlO mAb was labeled with biotin; purified unlabeled chimeric AlO and mouse AlO antibodies were examined for their ability to inhibit the binding of labeled AlO antibody to target cells (LS174T colon tumor).
  • the chimeric AlO and mouse AlO antibodies were identical in inhibition of the binding of labeled AlO antibody to LS174T tumor cells (Table 1).
  • Biotinylated mouse AlO antibody was incubated with LS174T tumor cells in the presence of the competing antibody at 4'C. Cells were washed free of unbound antibody, and then incubated with avidin peroxidase. A fall in the absorbance at 490 nm (Aagg) was used as a measure of relative inhibition of binding by biotinylated AlO.
  • b Human IgG is used as a nonspecific antibody control.
  • LS174T tumor cells were labeled with 51Cr, washed, and incubated with freshly isolated peripheral blood leukocytes in the presence of 17% human serum at a ratio of 50 leukocytes per tumor cell for 4 hours at 37'C.
  • the amount of ⁇ -lCr -released into the medium was used to calculate the % cytolysis as compared to cells lysed by the addition of 1% NP40.
  • E. coli Bacteria are suited for production of chimeric antibodies expressed from mammalian cDNA since entire coding sequences can be expressed from well characterized promoters.
  • E. coli is one of many useful bacterial species for production of foreign proteins (Holland et al ., BioTechnology 4:427 (1986)) since a wealth of genetic informa ⁇ tion is available for optimization of its gene expression.
  • E. coli can be used for production of foreign proteins internally or for secretion of proteins out of the cytoplasm, where they most often accumulate in the periplasmic space (Gray et al . , Gene 39:247 (1985); Oka et al., Proc. Nat! . Acad. Sci. USA 82: 7212 (1985)).
  • a Fab molecule consists of two nonidentical protein chains, the intact antibody L chain and the V, J, and C ⁇ l portions of the antibody H chain (Fd), linked by a single disulfide bridge.
  • the proper cDNA clones for the AlO chimeric L and Fd genes have already been identi ⁇ fied.
  • these cDNA clones were organized into a single bacterial operon (a dicistronic message) as gene fusions to the pectate lyase (pelB) gene leader sequence from Erwinia carotovora (Lei, et al, J. Bacteriol . 169: 4379 (1987)) and expressed from a strong regulated promoter.
  • Erwinia carotovora codes for several pectate lyases (polygalacturonic acid trans-eliminase) (Lei et al , Gene 35: 63 (1985)). Three pectate lyase genes have been cloned, and the DNA sequence of these genes has been determined. When cloned into E. coli under the control of a strong promoter, the pelB gene is expressed and large quantities of pectate lyase accumulate in the periplasmic space and culture supernatant. The pelB signal sequence functions efficiently in E. coli and was used as a secretion signal for antibody genes in this example.
  • the nucleotide sequence surrounding the signal sequence of the pelB gene is published (Lei, et a!.,1987, supra).
  • the pelB signal sequence contains a Haelll restriction site at amino acid 22, adjacent to the signal peptidase cleavage site: ala-ala.
  • Plasmid pSS1004 (Lei, et al ., 1987, supra) containing the pelB gene in pUC8 (Vierra and Messing 1982, Gene 19: 259), was digested with Haelll and EcoRI. This DNA was ligated with an eight base pair Sstl linker to SSPI and EcoRI cut pBR322.
  • the resulting plasmid contained a 300 bp fragment which included the 22 amino acid leader sequence of pelB and about 230 bp of upstream E. caratovora DNA.
  • This plasmid, pING173, contains an insert that upon digestion with Sstl and treatment with T4 DNA polymerase can be ligated directly to a DNA fragment flanked by the first amino acid of a mature coding sequence for any gene to generate a protein fusion containing a functional bacterial leader sequence in frame with the incoming gene.
  • the Sstl to EcoRI restric ⁇ tion fragment in pING173 was cloned into pUCl ⁇ (Yanich-Perron et al ..
  • Plasmid pING1500 derived from pRR175, contains only the region from the -48 of the pelB gene to an Xh ⁇ I site downstream of the pelB leader, and includes the Sstl site at the junction.
  • Site directed in vitro mutagenesis was performed as described by Kramer et al ., supra, to introduce an Sstl restriction site (see Figure 2) into the AlO K chain cDNA sequence in pTK4 (see Figure 4) at the junction of the leader peptide and mature coding region with the oligonucleotide primer 5'-GAGAACAATTTGAGCTCTGGACAGT-3', generating pTK6.
  • a Pstl site (see Figure 1) was similarly introduced at the junction of the leader peptide and mature coding region of the AlO H chain cDNA sequence in pTK3 with the oligonucleotide primer 5'-AAGCTTCACTTCTGCAGGGACACCATTT-3', generating pTKll ( Figure 2).
  • the chimeric AlO VL region containing an Sstl restriction site at the signal sequence processing site and a unique Hindlll site in the J-region of pTK6 served as the starting point for bacterial expres ⁇ sion.
  • the plasmid pTK6 was cut with S_stl, treated.with T4 polymerase, and digested with Sail, Figure 5A, (the Sail site is located outside of the antibody gene segment in the adjacent M13 multicloning region).
  • the approximately 380 bp fragment containing the VL region was purified and ligated to pING1500 that was cut with Sstl, treated with T4 polymerase, and cut with Sail, Figure 5B, generating pTK8.
  • the plasmid pTK8 containing a pe!B::A10 VL region fusion was sequenced to determine that the proper in-frame fusion was formed.
  • a Hindlll fragment from pTK8 containing the pelB leader sequence joined to the AlO V-J region was cloned into pS2D, a plasmid that contained the human C ⁇ region, generating pTK9, Figure 5C. 4. Preparation of Fd for Bacterial Expression
  • the intact AlO chimeric Fd gene containing a Pstl restriction site at the signal sequence processing site and a BstEII restriction site in the J-region in pTKll served as the starting point for bacterial expression.
  • the plasmid pTKll was cut with Pstl, treated with T4 polymerase, and digested with BstEII, Figure 5D.
  • the approxi ⁇ mately 340 bp fragment containing the Fd V-region was purified and ligated to pING1500 that was cut with Sstl, treated with T4 polymerase, and cut with Xhol, Figure 5E, along with the BstEII (partial digest) to Xhol restriction fragment containing the human Fd C region and 3 nucleotides following the termination codon from pF3D, Figure 5F, (the human C ⁇ l region in pF3D was previously generated by introducing a stop codon in hinge, Robinson, R.R. et al . , supra) .
  • the resulting plasmid that contained a pelB::A10 Fd fusion was sequenced to determine that the proper in-frame fusion was formed. This plasmid was called pTK13.
  • both the L chain and the Fd need to be produced simultaneously within the cell.
  • plasmids constructed with each of these genes separately, a series of expression vectors were constructed that contain both genes aligned so that transcription from a single promoter will specify both genes. This was done in a way that minimized the noncoding DNA between the two genes.
  • Each gene has a ribosome binding site needed for transla ⁇ tion initiation and the identical DNA sequence from -48 to the pelB leader::antibody gene junction.
  • Plasmid pTK9 was cut with Sphl, treated with T4 polymerase, cut with EcoRI, and the vector fragment was purified, Figure 5G. Simi ⁇ larly, pTK13 was cut with Xhol, treated with T4 polymerase, cut with EcoRI and the fragment containing the Fd gene was purified, Figure 5H. These two purified DNA fragments were ligated to produce pTK15, which contained the two AlO chimeric gene fusions linked in close proximity. The two gene cistron was placed under the control of the araB promoter in pING3104.
  • Plasmid pTK15 was cut with Sjjhl, treated with T4 polymerase, cut with Xhol, and the fragment containing the Fd and K genes was purified, Figure 51. This DNA fragment was ligated to the vector fragment from pING3104 that had been cut with EcoRI, treated with T4 polymerase, and cut with Xhol, Figure 5J, generating pING3204. This vector contains all the necessary features for expression of AlO chimeric Fab in E. coli.
  • AlO chimeric Fab from pING3204 in E. coli is under the inducible control of the araB promoter. Upon arabinose induction, Fab secreted into the growth medium increases more than 10 fold. Uninduced bacterial colonies harboring pING3204 were phenotypically indistinguishable from E. coli harboring pING3104.
  • the strain harboring pING3204 was cultured at 32 ⁇ C in 10L of minimal medium, supplemented with 1.7% glycerol as the carbon source. Dissolved oxygen was maintained at 20% of saturation by addition of a 5X concentrate of glycerol-supplemented minimal medium. The culture was induced at with 0.0 ⁇ % arabinose for greater than 16 hours in a 14L fermenter (Chemap). Fab was detected in the fermentation broth by ELISA.
  • the total amount of protein was estimated by a colorimetric assay, and the sample was loaded onto a carboxy ethylcellulose type (CM52, Whatman) column at a ratio of lOmg total protein per lg CM ⁇ 2 (pre-equilibrated with lOmM sodium phosphate buffer at pH 6.8).
  • the CM ⁇ 2 column was eluted with a linear gradient of increasing NaCl concentration (0-0.IN) in the same phosphate buffer.
  • the fractions containing Fab were further analyzed by SDS-PAGE and then pooled.
  • the combined Fab fractions were concentrated over a YM10 membrane to an Fab concentration of about 1 mg/ml, and stored frozen.
  • the AlO Fab purified from E. coli has identical molecular weight properties as other Fab molecules produced from E. coli, as assessed by SDS gel electrophoresis.
  • the bacterially-produced AlO Fab is correctly assembled as a K + Fd chain di er because of its positive reaction in the ELISA which detects molecules with both K and Fd determinants, and because it reacts with antigen positive cell lines.
  • the E. coli AlO Fab was shown to bind to antigen positive cell by performing direct and competition binding assays with the human carcinoma cell line LS174T.
  • direct binding assay Fab bound to the same target cancer cells as did mouse AlO antibody, but not to a control cell line which lacks the antigen.
  • competition assay using 125 I - labeled mouse AlO antibody the E. coli-derived chimeric AlO Fab inhibited binding of radiolabeled mouse AlO mAb to the human tumor cell line LS174T.
  • Fifty percent inhibition of AlO mAb binding by the yeast-derived Fab occurred at a concentration of about 1 ⁇ g/ml (Table 3), about the same concentration at which AlO mouse mAb showed ⁇ 0% inhibition.
  • Yeast derived AlO Fab inhibited the binding of mouse AlO antibody and mouse AlO Fab to LS174T tumor cells.
  • THe mouse Fab was prepared by papain digestion of mouse whole 939 antibody.
  • a ⁇ I-labeled AlO antibody was incubated with LS174T tumor cells in the presence of the competing antibody at 4 ⁇ C. Cells were washed free of unbound antibody, and cell-bound radioactivity was used to deter ⁇ mine the % inhibition of binding.
  • b Prepared by papain treatment c Human-IgG was used as a nonspecific antibody control.
  • yeast cells are capable of expressing and secreting foreign proteins.
  • yeast serve as a host for the production of mouse-human chimeric Fab.
  • This reagent may prove useful in cancer diagnosis by in vivo imaging of appropriately labeled Fab, and in cancer therapy by administration of the Fab as a drug, radionucl de, or toxin immunoconjugate.
  • Saccharomyces cerevisiae strain PS6 (ura3 leu2 MATa) was developed at INGENE and used as a host for yeast transformations performed as described by Ito et al . , J. Bacteriol. 153: 163-168 (1983). Yeast transformants were selected on SD agar (2% glucose, 0.67% yeast nitrogen base, 2% agar) and grown in SD broth buffered with 50mM sodium succinate, pH5.5.
  • Plasmid pTK6 ( Figure 5) was cut with Sstl, treated with T4 polymerase, and cut with Hindlll. The V-region fragment was ligated along with the human CL region prepared from pMID (the same fragment as contained in pS2D, see Example 2 and Figure S) as a
  • the plasmid pING1149 contains the gene sequence encoding the yeast invertase signal sequence
  • the resultant plasmid pTK12, Figure 6A contains the PGK promoter (P) along with the invertase signal sequence (S) fused to the AlO coding sequence.
  • P PGK promoter
  • S invertase signal sequence
  • the PGK promoter - invertase signal sequence - chimeric L chain (V,C K ) fusion was cloned into a partial 2 micron circle (2 /.), ura yeast expression vector containing the PGK polyadenyl tion signal (T ) to generate pTK16 ( Figure 6B) .
  • the PGK promoter-invertase signal sequence - chimeric Fd chain (V,C ⁇ l) fusion was cloned into a partial 2 micron circle (2 ) expres ⁇ sion vector containing the PGK polyadenylation signal (Tm) to generate pTK17 ( Figure 6D).
  • a single yeast expression vector containing both the chimeric L chain and Fd chain genes and their respective expression signals was constructed from pTK17 and pTK16.
  • the plasmid pING3203 was transformed into S. cerevisiae PS6 and the transformants were grown in broth under selective conditions as described above.
  • the culture supernatants were assayed by ELISA and contained Fab levels of approximately 100 ng/ml. This material can be purified from this fermentation broth and is expected to have proper- ties identical to those of Fab produced as described in example 2; yeast AlO Fab is expected to bind to LS174T cells.
  • both the chimeric AlO antibody and its Fab derivative bind to human tumor cell lines to the same extent as the mouse AlO antibody with approximately the same avidity.
  • the chimeric AlO antibody is significant because it binds to the surface of human tumor cells.
  • the AlO mAb has minimal reactivity to normal cells such as fibroblasts, endothelial cells, or epithelial cells in the major organs.
  • the chimeric AlO mAb defines an antigen that is useful in vitro for detecting and distin ⁇ guishing human tumor cells.
  • mAb therapy has been met with only limited success (Houohton et al., Proc. Natl . Acad. Sci. 82:1242-1246 (1985)) .
  • the therapeutic efficacy of unmodified mouse mAbs appears to be too low for most practical purposes.
  • the chimeric AlO is an improved therapeutic agent over the mouse AlO mAb for the treatment of human tumors in vivo.
  • the high biological activity of the chimeric AlO antibody against human tumor cell lines combined with minimal reactivity with normal tissues imply that this antibody may mediate the destruction of malignant tissue.
  • the "more human” chimeric AlO antibody will be more resistant to rapid clearance from the body than the mouse AlO antibody.
  • the human component of a chimeric antibody may enhance its ability to mediate target destruc ⁇ tion in combination with human effector cells or complement.
  • the enhanced resistance to clearance means that chimeric AlO antibodies and their derivatives can be advantageously used for the diagnosis and therapy of tumors in the form of immunoconjugates with drugs, toxins, immunomodulators, radionuclides, etc.
  • immuno ⁇ conjugates, and techniques to form them are known to those skilled in the art and can be used to modify the chimeric AlO antibody within the scope of the present invention.
  • any desired antibody isotype can be combined with any particular antigen combining site.
  • This invention also enables the direct production of one or more domains of the antibody molecule in func ⁇ tionally active form.
  • E. coli MC 1061 (pING3204), designated strain G268 (ATCC Accession # 68071)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticorps chimérique possédant une région constante humaine et une région variable murine, ayant une spécificité envers des cellules tumorales humaines, ses méthodes de production, et applications.
EP19910900650 1989-11-13 1990-11-13 Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen Withdrawn EP0457875A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43501289A 1989-11-13 1989-11-13
US435012 1989-11-13

Publications (2)

Publication Number Publication Date
EP0457875A1 true EP0457875A1 (fr) 1991-11-27
EP0457875A4 EP0457875A4 (en) 1993-03-03

Family

ID=23726623

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910900650 Withdrawn EP0457875A4 (en) 1989-11-13 1990-11-13 Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen

Country Status (6)

Country Link
EP (1) EP0457875A4 (fr)
JP (1) JPH03206886A (fr)
KR (1) KR910009284A (fr)
AU (1) AU634314B2 (fr)
CA (1) CA2044590A1 (fr)
WO (1) WO1991007418A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
ES2210514T3 (es) * 1996-04-10 2004-07-01 Sangstat Medical Corporation Conjugados citomoduladores de miembros de pares de union especificos.
IT1289608B1 (it) * 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
IL151927A0 (en) 2000-03-31 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US20030138440A1 (en) 2001-07-19 2003-07-24 Fang Fang Multimeric proteins and methods of making and using same
AU2003243226A1 (en) 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
EP2529758A3 (fr) 2003-01-27 2013-01-02 Endocyte, Inc. Conjugués d'administration de médicaments à liaison au récepteur de vitamines
WO2006012527A1 (fr) 2004-07-23 2006-02-02 Endocyte, Inc. Groupes de liaison bivalents et conjugués de ceux-ci
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
US20080280937A1 (en) 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
JP2011500835A (ja) 2007-10-25 2011-01-06 エンドサイト，インコーポレイテッド チューブリシン類および調製プロセス
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
WO2013126797A1 (fr) 2012-02-24 2013-08-29 Purdue Research Foundation Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
PE20211760A1 (es) 2013-10-18 2021-09-07 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
MX2023012114A (es) 2021-04-16 2023-10-24 Novartis Ag Agentes radioterapeuticos dirigidos al receptor de folato y su uso.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323806A1 (fr) * 1988-01-05 1989-07-12 Ciba-Geigy Ag Anticorps chimériques
EP0323805A2 (fr) * 1988-01-05 1989-07-12 Buchegger, Franz Anticorps
EP0332424A2 (fr) * 1988-03-09 1989-09-13 Hybritech Incorporated Anticorps chimériques, dirigés contre l'antigène humaine carcino-embryonique
EP0125023B1 (fr) * 1983-04-08 1991-06-05 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023B1 (fr) * 1983-04-08 1991-06-05 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
EP0323806A1 (fr) * 1988-01-05 1989-07-12 Ciba-Geigy Ag Anticorps chimériques
EP0323805A2 (fr) * 1988-01-05 1989-07-12 Buchegger, Franz Anticorps
EP0332424A2 (fr) * 1988-03-09 1989-09-13 Hybritech Incorporated Anticorps chimériques, dirigés contre l'antigène humaine carcino-embryonique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9107418A1 *

Also Published As

Publication number Publication date
EP0457875A4 (en) 1993-03-03
AU634314B2 (en) 1993-02-18
KR910009284A (ko) 1991-06-28
CA2044590A1 (fr) 1991-05-14
AU6664190A (en) 1991-05-23
JPH03206886A (ja) 1991-09-10
WO1991007418A1 (fr) 1991-05-30

Similar Documents

Publication Publication Date Title
AU634314B2 (en) Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
EP0364096B1 (fr) Eléments d'expression de gènes et production d'anticorps souris-humains chimériques
US5843685A (en) Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0731167B1 (fr) Assemblage modulaire de gènes d'anticorps, anticorps ainsi préparés et leurs utilisations
EP0266663B1 (fr) Anticorps chimérique spécifique pour antigène à tumeur humaine
US5500362A (en) Chimeric antibody with specificity to human B cell surface antigen
US5576195A (en) Vectors with pectate lyase signal sequence
US5618920A (en) Modular assembly of antibody genes, antibodies prepared thereby and use
US20050163708A1 (en) Chimeric antibody with specificity to human B cell surface antigen
EP0404003A2 (fr) Anticorps KM10 chimériques souris-humains, ayant une spécificité pour un antigène de cellules humaines tumorales
US20050196400A1 (en) Production of chimeric mouse-human antibodies with specificity to human tumor antigens
AU606653C (en) Chimeric antibody with specificity to human B cell surface antigen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19940808

R18W Application withdrawn (corrected)

Effective date: 19940808